Ainos, Inc., a dual-platform company, focusing artificial intelligencebased smelltech technologies and immune therapeutics. It offers AI Nose, an AI-based electronic olfaction system, which uses a smell language model to digitize scent into Smell IDs and turning into machine-readable data. The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries; as well as senior care and women's health sectors. In addition, it develops VELDONA, a low-dose oral interferon platform for human and animal health applications, targeting rare, autoimmune, and infectious diseases. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in Houston, Texas. Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation.
0 transactions — 0 buys and 0 sales reported by Ainos, Inc. executives.
0 institutional funds report a position on AIMD in their latest SEC quarterly filing.
15 recent articles on AIMD.
Beyond raw data, we aggregate and score every smart money signal to give you a unique view.
8-dimension composite score: insiders · hedge funds · politicians · momentum · valuation · health · analysts · earnings.
Detection of clustered purchases or sales by several executives in the same stock.
Berkshire, Pershing Square, Tiger Global, Bridgewater and other reporting funds.
NANC & GOP (Pelosi & Republicans), GURU (top hedge funds), ARK (Cathie Wood). See who enters and exits each week.
Spot marked changes in search interest around the stocks being followed.
Create your watchlist and receive a brief of events affecting your tickers.
This public page only shows a preview. The full analysis of AIMD on the Kairos Insider dashboard includes:
Free signup · Pro €19/month or €190/year